
    
      This is a 28-day randomized, observer-masked, placebo-and active-controlled, parallel-group,
      multi-center, study investigating the safety and efficacy of four concentrations of DE-117
      ophthalmic solution when compared to latanoprost (0.005% latanoprost) and placebo (vehicle of
      DE-117) in subjects with primary open-angle glaucoma or ocular hypertension.
    
  